<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580563</url>
  </required_header>
  <id_info>
    <org_study_id>7572</org_study_id>
    <nct_id>NCT04580563</nct_id>
  </id_info>
  <brief_title>Study Assessing Efficacy of Plasmatherapy in Septic Shock-induced Coagulopathy: Feasibility Study</brief_title>
  <acronym>PlasmaFaisa</acronym>
  <official_title>Prospective Randomized Versus Placebo Study Assessing Efficacy of Plasmatherapy in Septic Shock-induced Coagulopathy: Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      No randomized controlled trial (RCT) has investigated the effect of prophylactic fresh frozen&#xD;
      plasma (FFP) transfusion in septic or critically ill patients with coagulation abnormalities.&#xD;
      The last Surviving Sepsis Campaign therefore suggests with a very low quality of evidence&#xD;
      &quot;against the use of fresh frozen plasma during septic shock to correct clotting abnormalities&#xD;
      in the absence of bleeding or planned invasive procedures&quot;. However, expert opinion&#xD;
      highlights that FFP should be transfused &quot;when there is a documented deficiency of&#xD;
      coagulation factors (increased prothrombin time, international normalized ratio - INR, or&#xD;
      partial thromboplastin time) and the presence of active bleeding or before surgical or&#xD;
      invasive procedures&quot;. Disseminated intravascular coagulation (DIC) is responsible for such a&#xD;
      severe deficiency of coagulation factors. Supplementing the intense deficit of coagulation&#xD;
      factors with plasma containing non-activated coagulation factors is therefore a rational&#xD;
      therapy in DIC patients.&#xD;
&#xD;
      OctaplasLG® is a donor plasma product, with unique features compared to standard fresh frozen&#xD;
      plasma: standardized concentrations of natural pro-/anti-coagulation factors; a standardized&#xD;
      volume; pathogen free. OctaplasLG® should reduce the &quot;inflammatory hit&quot; on the endothelium,&#xD;
      including the glycocalyx, by having standardized levels of coagulation proteins, which can&#xD;
      give more sustainable support to the endothelial regeneration as compared to standard fresh&#xD;
      frozen plasma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present RCT is an open-label faisability study. OctaplasLG® or a placebo (0.9% NaCl) will&#xD;
      be allocated to patients with a septic shock-induced coagulopathy defined by decreased&#xD;
      platelets (&lt;150,000/mm3 or &gt;30% decrease within 24 hours) and an INR&gt;1.40, and started within&#xD;
      the 6 hours following coagulopathy diagnosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 4, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>delays between the diagnosis of coagulopathy and the administration of treatment</measure>
    <time_frame>Day 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Septic Shock</condition>
  <condition>Coagulopathy</condition>
  <condition>Disseminated Intravascular Coagulation</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group will receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 if prothrombin time is below 50%.&#xD;
OctaplasLG® is a donor plasma product, with unique features compared to standard fresh frozen plasma: standardized concentrations of natural pro-/anti-coagulation factors; a standardized volume; pathogen free. OctaplasLG® should reduce the &quot;inflammatory hit&quot; on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 if prothrombin time is below 50%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OctaplasLG®</intervention_name>
    <description>Patient receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 if prothrombin time is below 50%.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% NaCl</intervention_name>
    <description>Patient receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 if prothrombin time is below 50%.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with:&#xD;
&#xD;
               -  a septic shock defined by Sepsis-3 criteria (Singer, JAMA 2016)&#xD;
&#xD;
               -  and a coagulopathy assessed by decreased platelets (&lt;150,000/mm3 or &gt;30% decrease&#xD;
                  within 24 hours) and an INR&gt;1.40 (Vincent, Crit Care Med 2013) without other&#xD;
                  etiology&#xD;
&#xD;
          -  Randomization within a timeframe of 6 hours after coagulopathy diagnosis&#xD;
&#xD;
          -  Age strictly over 18 years old&#xD;
&#xD;
          -  Subject affiliated to a social health insurance&#xD;
&#xD;
          -  Free and informed consent dated and signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to OctaplasLG®&#xD;
&#xD;
          -  Contraindication to preventive anticoagulation by heparin&#xD;
&#xD;
          -  Any disorder with a requirement for full anticoagulation on the day of randomization&#xD;
&#xD;
          -  PT prolongation or thrombocytopenia that is not due to sepsis&#xD;
&#xD;
          -  History of congenital bleeding disorder predisposing to hemorrhage&#xD;
&#xD;
          -  Medical condition associated with a hypercoagulable state&#xD;
&#xD;
          -  Patient moribund on the day of randomization&#xD;
&#xD;
          -  Do not resuscitate limitation at inclusion in the study&#xD;
&#xD;
          -  Law protection: guardianship or curatorship&#xD;
&#xD;
          -  Pregnancy/breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie HELMS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>septic shock</keyword>
  <keyword>coagulopathy</keyword>
  <keyword>disseminated intravascular coagulation</keyword>
  <keyword>- plasmatherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Disseminated Intravascular Coagulation</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

